-
Moderna gets $176M to develop mRNA flu shots
The HHS has awarded Moderna $176 million to expand its capabilities to develop mRNA-based pandemic influenza vaccines. -
FTC probes Teva over drug patents
The FTC has launched a probe into Teva Pharmaceuticals over contested drug patents the company refuses to remove from a federal registry, The Washington Post reported July 1. -
Chevron ruling may hinder drug development, experts say
Former FDA attorneys say the Supreme Court's recent decision to overturn Chevron deference, a decades-old legal precedent, could stall the development of new drugs and medical devices, Politico reported July 1. -
Payment trends for pharmacist services gaining steam
If current trends continue, Michael Murphy, PharmD, said all payers will come to recognize pharmacists as healthcare providers by the end of the decade. -
Ochsner Health's innovative approach to mitigating oncology drug shortages
In the last year, the field of oncology has continued to grapple with significant challenges that have imposed formidable hurdles on cancer care worldwide. -
Cancer drug shortage ends
The national supply of the cancer drug cisplatin now exceeds demand, FDA Commissioner Robert Cailiff, MD, said June 28. -
InflaRx’s GOHIBIC (Vilobelimab) selected for first BARDA-sponsored clinical trial to evaluate novel host-directed therapeutics for acute respiratory distress syndrome (ARDS)
InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as one of three investigational therapies to be assessed in a Phase 2 clinical platform study exploring potential new options for the treatment of acute respiratory distress syndrome (ARDS). -
FDA approves 1st inhaled COPD treatment in 20 years
An inhalable drug treatment for chronic obstructive pulmonary disease received FDA-approval June 26, drugmaker Verona Pharma announced. -
All 71 CHS hospitals to use Mark Cuban's drug wholesale services
Mark Cuban Cost Plus Drug Co. will serve as a wholesale drug distributor for all 71 hospitals affiliated with Community Health Systems, the organizations announced June 27. -
10 numbers on prescription drug costs: GoodRx
Between 2014 and 2024, prescription medication prices have increased 37%, according to a GoodRx, which launched a prescription cost tracker June 26. -
Mail-order medications pushing employers' costs up: Report
Mail-ordered prescriptions were supposed to be cheaper, but these medications are costing more than those picked up at pharmacy counters, The Wall Street Journal reported June 25. -
Cancer drug shortages 'a moving target,' cancer centers say
A year after multiple popular oncology treatments were in short supply, U.S. cancer centers are still struggling to stock enough cancer therapies. -
New Jersey drugmaker recalls 144 batches
Glenmark Pharmaceuticals Inc., USA, is voluntarily recalling 144 batches of potassium chloride extended-release capsules because of failed dissolution, the FDA said June 25. -
Ozempic maker plans $4.1B manufacturing plant
Novo Nordisk is planning to build a $4.1 billion manufacturing plant in Clayton, N.C., to help meet demand for its blockbuster drugs Ozempic and Wegovy. -
Why Echo Dots are stationed across Houston Methodist
"Alexa, what are the side effects of amoxicillin?" -
J&J acquires immune disease biologics company for $850M
Johnson & Johnson has completed its $850 million acquisition of Proteologix, a biologics company that specializes in developing treatments for immune-mediated diseases, it announced June 21. -
Eli Lilly hits phony drugmakers with 6 more lawsuits
Counterfeit versions of Eli Lilly's blockbuster GLP-1 anti-obesity medications Mounjaro and Zepound are under fire from the drugmaker as it intensifies legal efforts to combat fraudulent and off-label cosmetic uses. -
Walgreens pursues provider status for pharmacists
Walgreens is on a mission to attain provider status for its pharmacists. -
UW Health's solution to limited pharmacy hours
As pharmacies trim operating hours, Madison, Wis.-based UW Health is improving convenience and increasing access with medication kiosks. -
Insured patients often save less with Mark Cuban's drug company: Study
Individuals with health insurance are more likely to spend less on generic drugs when using their benefits compared to going through Mark Cuban's Cost Plus Drug Company, according to a study published June 14 in JAMA Health Forum.
Page 21 of 50